Format

Send to

Choose Destination
Curr Opin Pharmacol. 2005 Aug;5(4):350-6.

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

Author information

1
Astex Technology Ltd, 436 Cambridge Science Park, Milton Rd, Cambridge CB4 0QA, UK.

Abstract

Since the discovery that activating mutations of the Ras GTPase were associated with 30% or more of human cancers, the RAF/MEK/ERK pathway has been the focus of intense drug discovery effort. Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise.

PMID:
15955734
DOI:
10.1016/j.coph.2005.04.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center